Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Cross Country Healthcare Sees Q1 EPS $0.15-$0.25 Vs $0.30 Est.; Revenue $370M-$380M Vs $399.04M Est.

Author: Benzinga Newsdesk | February 21, 2024 07:29pm

Outlook for First Quarter 2024


 

The guidance below applies only to management's expectations for the first quarter of 2024.

                  
 Q1 2024 Range Year-over-Year Sequential
Change Change
      
Revenue$370 million - $380 million (41)% - (39)% (11)% - (8)%
      
Adjusted EBITDA*$13.0 million - $18.0 million (75)% - (65)% (37)% - (13)%
      
Adjusted EPS*$0.15 - $0.25 $(0.69) - $(0.59) $(0.14) - $(0.04)


 

* Refer to discussion of non-GAAP financial measures and reconciliation tables below.


 

The above estimates are based on current management expectations and, as such, are forward-looking and actual results may differ materially. The above ranges do not include the potential impact of any future divestitures, mergers, acquisitions, or other business combinations, changes in debt structure, or future significant share repurchases.

Posted In: CCRN